Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma-Reference-Cited by-同舟云学术

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Published:2022-12 Issue:3 Volume:167 Page:404-413
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

O'Malley David M.,Oza Amit M.,Lorusso Domenica,Aghajanian Carol,Oaknin Ana,Dean Andrew,Colombo Nicoletta,Weberpals Johanne I.,Clamp Andrew R.,Scambia Giovanni,Leary Alexandra,Holloway Robert W.,Gancedo Margarita Amenedo,Fong Peter C.,Goh Jeffrey C.,Swisher Elizabeth M.,Maloney Lara,Goble Sandra,Lin Kevin K.,Kwan Tanya,Ledermann Jonathan A.,Coleman Robert L.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference23 articles.

1. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial;Coleman;Lancet,2017

2. Going to extremes: determinants of extraordinary response and survival in patients with cancer;Saner;Nat. Rev. Cancer,2019

3. Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: clinical and molecular characterization;Lheureux;Clin. Cancer Res.,2017

4. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer;Swisher;Gynecol. Oncol.,2021

5. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal;Sun;PLoS Comput. Biol.,2018

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene;Genetics in Medicine;2024-10

2. The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research;Molecular Cancer;2024-08-14

3. Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients;Gynecologic Oncology;2024-08

4. Limitations of homologous recombination status testing and poly (ADP-ribose) polymerase inhibitor treatment in the current management of ovarian cancer;Frontiers in Oncology;2024-07-22

5. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer;JAMA Network Open;2024-04-22